Cerebrospinal fluid cytoskeleton proteins in patients with subcortical white-matter dementia

Mechanisms of Ageing and Development

Volumn 122, Issue 16, 2001, Pages 1937-1949

  Wallin, Anders ^a   Sjögren, Magnus ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Albumin ratio; Dementia; Neurofilament; Subcortical; Tau; White matter

Indexed keywords

APOLIPOPROTEIN E4; CYTOSKELETON PROTEIN; NEUROFILAMENT PROTEIN; TAU PROTEIN;

ADULT; AGED; ALLELE; BLOOD BRAIN BARRIER; BLOOD VESSEL INJURY; BLOOD VESSEL WALL; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MULTIINFARCT DEMENTIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RISK FACTOR; VASCULAR DISEASE; WHITE MATTER;

AGED; AGED, 80 AND OVER; CYTOSKELETAL PROTEINS; DEMENTIA, VASCULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROFILAMENT PROTEINS; TAU PROTEINS;

EID: 0034815757     PISSN: 00476374     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0047-6374(01)00306-2     Document Type: Conference Paper

References (71)

1. 'Vascular depression' hypothesis
2. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: A community based follow up study
3. Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease
4. No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia
5. White matter lesions on CT in Alzheimer's disease-relation to clinical symptomatology and vascular factors
6. Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease?
7. Conceptual background of vascular cognitive impairment
8. A white matter disorder in dementia of the Alzheimer type
9. Is 'Parkinson's disease' one disease?
10. Subcortical ischemic vascular dementia: Assessment with quantitative MR imaging and 1H MR spectroscopy
11. Quantitative cerebral anatomy in depression. A controlled magnetic resonance imaging study
12. Cognitive correlates of cerebral white matter changes
13. Cerebral white matter lesions and cognitive function: The Rotterdam Scan Study
14. Neuropathology of white matter disease: Parenchymal changes
15. Limitations of clinical criteria for the diagnosis of vascular dementia in clinical trials. Is a focus on subcortical vascular dementia a solution?
16. The relevance of white matter changes to vascular dementia
17. Mini-mental State A practical method for grading the cognitive state of patients for the clinician
18. Axon calibre, neurofilaments, microtubules, sheath thickness and cholesterol in cat optic nerve fibres
19. Tau protein and the neurofibrillary pathology of Alzheimer's disease
20. Subcortical vascular dementia as a specific target for clinical trials
21. Leuko-araiosis
22. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke
23. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: A study in Japan
24. A method for the identification of apolipoprotein E isoforms employing chemical precipitation and flat bed isoelectric focusing in agarose
25. Axonal disruption and aberrant localization of tau protein characterize the neurophil pathology of Alzheimer's disease
26. Studying the intrinsic determinants of neuronal form and function
27. Cognition and white matter hyperintensities in older depressed patients
28. Subcortical arteriosclerotic encephalopathy: CT spectrum and pathologic correlation
29. Clinical and neuropathological criteria for frontotemporal dementia
30. Neurofilament protein in cerebrospinal fluid: A potential marker of activity in multiple sclerosis
31. Tau protein in cerebrospinal fluid: A new diagnostic and prognostic marker in Alzheimer disease?
32. Tau in cerebrospinal fluids: Establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau
33. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease
34. Variable agreement between visual rating scales for white matter hyperintensities on MRI. Comparison of 13 rating scales in a poststroke cohort
35. Pathogenesis of leukoaraiosis: A review
36. Cerebrospinal fluid proteins in patients with leucoaraiosis: Possible abnormalities in blood-brain barrier function
37. A preliminary open trial with nimodipine in patients with cognitive impairment and leukoaraiosis
38. Efficacy and safety of nimodipine in subcortical vascular dementia: A subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial
39. The neuropathology of myelin disease
40. Cerebrovascular disease and late life depression: An age old association revisited
41. Effects of enzymatic brain defibrination in subcortical arteriosclerotic encephalopathy
42. Executive control function: A rational basis for the diagnosis of vascular dementia
43. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF
44. Neurofilament protein levels in CSF are increased in dementia
45. Neuropsychological impairment correlates with hypoperfusion and hypometabolism but not with severity of white matter lesions on MRI in patients with cerebral microangiopathy
46. White matter changes on CT and MRI, 1998. An overview of visual rating scales
47. MRI white matter hyperintensities: Three-year follow-up of the Austrian Stroke Prevention Study
48. Cerebral perfusion in hypertensives with carotid artery stenosis: A comparative study of lacidipine and hydrochlorothiazide
49. Pathophysiological aspects of frontotemporal dementia-emphasis on cytoskeleton proteins and autoimmunity
50. CSF levels of tau, B-amyloid42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging
51. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD
52. Regional CBF and CT/MRI distinguish frontotemporal dementia from Alzheimer's disease and subcortical white-matter dementia
53. Characteristics of growth-associated polypeptides in regenerating toad retinal ganglion cell axons
54. A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: Relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele
55. A population study of apoE genotype at the age of 85: Relation to dementia, cerebrovascular disease, and mortality
56. A population study on blood-brain barrier function in 85-year-olds: Relation to Alzheimer's disease and vascular dementia
57. The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease
58. Intrathecal production of tumor necrosis factor-α, a local neuroprotective agent, in Alzheimer disease and vascular dementia
59. Epidemiology of vascular dementia
60. Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values
61. CSF neurofilament and glial fibrillary acidic protein in normal pressure hydrocephalus
62. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay
63. Heterogeneity of vascular dementia-mechanisms and subgroups
64. Decreased myelin lipids in Alzheimer's disease and vascular dementia
65. Blood-brain barrier function in vascular dementia
66. Subcortical symptoms predominate in vascular dementia
67. Stepwise comparative status analysis (STEP) - A tool for the identification of various regional brain syndromes in dementia
68. Symptoms, vascular risk factors and blood-brain barrier function in relation to CT white-matter changes in dementia
69. Amyloid precursor protein accumulates in white matter at the margin of a focal ischaemic lesion